Health status was assessed at baseline, 1 month, 1 year, and 2 years using the Kansas City Cardiomyopathy Quest ionnaire (KCCQ) (23 items covering physical function, social function, symptoms, self-efficacy and knowledge, and quality of life on a 0-to 100-point scale; higher scores indicate better quality of life), Medical Outcomes Study Short Form-36 (36 items covering 8 dimensions of health status as well as physical and mental summary scores; higher scores represent better health status), and EuroQOL-5D (assesses 5 dimensions of general health on a 3-level scale, with utility scores ranging from 0 [death] to 1 [ideal health]). Analysis of covariance was used to examine changes in health status over time, adjusting for baseline status.
P atients with severe, symptomatic aortic stenosis (AS) benefit from aortic valve replacement both in terms of survival and quality of life (QOL).
1-3 While surgical aortic valve replacement (SAVR) has long been the standard of care for treatment of AS, over the past decade, transcatheter aortic valve replacement (TAVR) has also been shown to be a viable treatment option for patients who are not suitable for SAVR or are at high risk for surgical complications. 4, 5 With growing experience and technological evolution, TAVR has been increasingly performed in patients at lower surgical risk. Recently, the Placement of Aortic Transcatheter Valve (PARTNER) 2 Cohort A trial demonstrated similar rates of death or disabling stroke at 2 years in patients at intermediate surgical risk treated with either SAVR or TAVR. 6 Although prolonged survival remains a key benefit of valve replacement for patients with AS, for many individuals (who are generally elderly and have multiple comorbid conditions), improved QOL is an equally important consideration. Prior studies have shown that TAVR results in substantial QOL benefits in patients with AS who are unsuitable for SAVR 7, 8 and an early QOL benefit compared with SAVR for patients at high surgical risk. 9, 10 However, this early QOL benefit has been restricted to patients treated via the transfemoral approach and has not been seen in patients treated via alternative access. Whether these results apply to patients at intermediate surgical risk is currently unknown. In particular, it is unclear whether differences in procedure-related complications (eg, bleeding, paravalvular regurgitation, or permanent pacemaker implantation) might result in long-term differences in health status between the 2 treatments. To address these gaps in knowledge, we performed a prospective study alongside the PARTNER 2A trial to compare both short-and long-term health status outcomes in intermediate-risk patients with AS treated with either TAVR or SAVR.
Methods

Study Design and Population
The design of the PARTNER 2A trial (NCT01314313) has been described. 6 Briefly, PARTNER 2A enrolled patients with severe, symptomatic AS at intermediate surgical risk at 57 sites in the United States and Canada. Severe AS was defined as (1) aortic valve area of 0.8 cm 2 or less or aortic valve area index 0.5 cm 2 /m 2 or less and (2) mean aortic valve gradient greater than 40 mm Hg or peak aortic jet velocity greater than 4.0 m/s. Patients were considered to be at intermediate surgical risk if they had a predicted 30-day surgical mortality of 4% to 8% as determined by the Society of Thoracic Surgeons mortality risk model (possible range of risk, 0%-100%; higher percentages indicate greater risk) 11 and a multidisciplinary heart team. Key exclusion criteria included patients with a congenitally bicuspid aortic valve, severe renal disease, predominant aortic regurgitation, or left ventricular ejection fraction less than 20%. All patients underwent imaging to determine eligibility for transfemoral or transthoracic access (direct aortic or transapical approach) for TAVR. Patients were then stratified according to access route and randomized 1:1 to undergo either TAVR, using the Sapien XT valve (Edwards LifeSciences) or SAVR. The trial was approved by the institutional review board at each site (eAppendix in Supplement), and written informed consent was obtained from all patients.
Measurement of Health Status
Health status was evaluated in all patients at baseline, 1 month, 1 year, and 2 years. Disease-specific health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a 23-item questionnaire that covers 5 key domains of health status in patients with heart failure (physical function, social function, symptoms, self-efficacy and knowledge, and quality of life) and is scored from 0 to 100, with higher scores indicating better QOL. The individual scales of the KCCQ may be converted into a single overall summary score (KCCQ-OS), which has been shown to correlate well with important clinical outcomes, including rehospitalization, health care costs, and death in heart failure populations. 12,13 The KCCQ-OS has also been shown to correlate with New York Heart Association functional class as follows: class I, 75-100; class II, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] class III, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] and class IV, 15 Small, moderate, and large clinical improvements have been shown to correspond with changes in the KCCQ-OS of approximately 5, 10, and 20 points, respectively. 15 Recent work by our group demonstrated the reliability and validity of this instrument for patients with AS.
14 Generic health status was evaluated using the Medical Outcomes Study Short-Form 36 (SF-36) questionnaire and the EuroQOL-5D (EQ-5D). The SF-36 assesses 8 dimensions of health status and has been validated in patients with cardiovascular disease. [16] [17] [18] In addition, the SF-36 provides physical and mental component summary scales, which are scored such that the US population mean (SD) is 50 (10), with higher scores representing better health status. The minimum clinically important differences for the SF-36 physical and mental summary scales are approximately 2 points. 19 The EQ-5D is a multiattribute health status classification system that assesses 5 dimensions of general health, using a 3-level scale, that are then transformed into preference-based utility weights using validated population sampling methods.
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These utilities range from 0 (death) to 1 (ideal health).
Statistical Analysis
The primary analysis compared the health status of patients randomized to TAVR vs SAVR on an intention-to-treat basis. A secondary analysis was performed, which included only patients who underwent their assigned treatment (per-protocol population). The primary end point was the KCCQ-OS score. All other QOL scales were considered secondary end points. Baseline characteristics were compared between the cohorts using 2-tailed t tests for continuous variables and χ 2 tests for categorical variables. Mean changes in health status scores at all time points were compared with baseline within each treatment group using paired t tests. For each health status measure, scores between treatment groups at each time point were compared using analysis of covariance, adjusting for differences in baseline health status. Since prior studies of TAVR have demonstrated that access site can be associated with different clinical and health status outcomes, 9,10 the analytic plan specified that, if a significant interaction (P < .05) between access site and treatment was observed on the KCCQ-OS at any time point, then all analyses would be stratified according to access site. Categorical analyses incorporating both health status and survival were also performed to provide further perspective on the effect of these interventions over time. For these analyses, ordinal categories based on previously established thresholds for clinically relevant changes in the KCCQ-OS score 15 were defined: death, worse (decrease from baseline >5 points), no change (change between −5 and <5 points), mildly improved (increase between 5 and <10 points), moderately improved (increase between 10 and <20 points), and substantially improved (increase ≥20 points). The relative effect of TAVR vs SAVR on health status was then compared between the 2 cohorts, using ordinal logistic regression after stratification for access site. Rates of substantial improvement and moderate improvement among surviving patients were also compared between TAVR and SAVR in the transfemoral and transthoracic groups, using logistic regression.
Results
Study Population
Of the 2032 patients randomized in the PARTNER 2A trial, baseline health status was available for 1833 patients (950 TAVR; 883 SAVR) who formed the primary analytic cohort. Baseline characteristics of the analytic cohort are summarized in Table 1 . Overall, the treatment groups were well matched. Mean (SD) age was 81.4 (6.8) years, and 1006 (54.9%) participants were men. The mean (SD) Society of Thoracic Surgeons mortality risk score was 5.8% (2.1%) for TAVR and 5.8% (1.9% for SAVR). Six hundred seventy-one (36.6%) patients had diabetes, 451 (24.6%) had undergone prior coronary artery bypass graft surgery, and 59 (3.2%) had chronic obstructive pulmonary disease requiring home oxygen. A total of 1393 (76.0%) patients were eligible for transfemoral access, and the remaining 440 (24.0%) required transthoracic access. Patients who required transthoracic access had higher rates of peripheral arterial disease, prior coronary artery bypass graft surgery, and prior stroke compared with transfemoral access patients. Baseline health status was significantly impaired in both groups. The mean (SD) KCCQ-OS score was 53 (21.6), which corresponds to New York Heart Association functional class III symptoms. The mean SF-36 physical summary score was 36 (8.8), which is approximately 1.5 SDs below the US population mean. There were no significant differences in baseline health status between the TAVR and SAVR groups in either access stratum.
Within-Group Comparisons
Health status data were available for 95%, 92%, and 88% of patients in the TAVR group at 1 month, 1 year, and 2 years, respectively, and for 87%, 84% and 84% at 1 month, 1 year, and 2 years in the SAVR group (eTable 1 in the Supplement). Baseline clinical characteristics were similar between patients with and without 2-year follow-up health status data (eTable 2 in the Supplement).
Among surviving patients, both disease-specific and generic health status improved substantially by 1-year after TAVR or SAVR, regardless of access site ( Table 2) , with mean improvements of 16 to 22 points on the KCCQ-OS scale, 3.9 to 5.1 points on the SF-36 physical summary scale, and 1.6 to 3.3 points on the SF-36 mental summary scale. Similar improvements were seen among surviving patients at 2-year follow-up.
Between-Group Comparisons
The comparisons of health status between the TAVR and SAVR groups are shown in Figure 1A and B as well as eTable 3 in the Supplement. Since there was evidence of a significant interaction between access site and treatment group for several key health status measurements at 1 month, all analyses were stratified by access site.
In the transfemoral group, TAVR resulted in a significantly greater early health status improvement compared with SAVR according to the KCCQ-OS score (1-month mean adjusted diSimilar benefits of TAVR were seen in the SF-36 physical summary scale (mean adjusted difference, 4.6 points; 95% CI, 3.7-5.5; P < .01) and the SF-36 mental summary scale (mean adjusted difference, 5.5 points; 95% CI, 4.3-6.8; P < .01). At 1 and 2 years, however, there were no significant differences between TAVR and SAVR on any of the disease-specific or generic health status instruments. In the transthoracic group, there were no significant differences in health status between TAVR and SAVR at 1 month (mean difference in KCCQ-OS, 3.5 points; 95% CI, −1.4 to 8.4; P < .01 for interaction) or at any time point on any health status measure.
Per-Protocol Results
Of the 1833 patients in the analytic cohort, 27 (1.5%) did not undergo the assigned procedure. The per-protocol cohort thus consisted of 1806 patients (945 TAVR; 861 SAVR). There were no meaningful differences in either the within-group or between-group comparisons in the per-protocol analyses compared with the intention-to-treat analyses (eTables 4 and 5intheSupplement).
Categorical Analyses
The results of categorical analyses are summarized in Table 3 and Figure 2 . At 1-month follow-up, the proportion of patients who experienced a substantial (≥20 points) improvement in the KCCQ-OS was significantly greater with transfemoral TAVR than SAVR (43.8% vs 26.9%; P < .01). No such benefit of TAVR was seen in the transthoracic cohort. At both 1-and 2-year follow-up, 45%-50% of surviving patients experienced a substantial improvement in the KCCQ-OS, with no significant difference between TAVR and SAVR in either the transfemoral or transthoracic cohorts. When change in health status was categorized as an ordinal variable with death as the worst possible outcome, transfemoral TAVR resulted in a substantial benefit compared with SAVR at 1 month and a small, but significant, benefit at 1 year and 2 years as well ( Figure 2A ). These benefits were driven by both small differences in survival as well as differences in the proportion of patients who experienced large health status benefits at the later time points. No significant differences were seen at any time point in the transthoracic cohort ( Figure 2B ).
Discussion
To our knowledge, this is the first study to compare the effects of TAVR with those of SAVR on detailed disease-specific and generic patient-reported health status in individuals with severe, symptomatic AS at intermediate surgical risk. In this population, patients who were treated with TAVR or SAVR demonstrated substantial and durable improvements in health status from baseline through 2 years. Among patients eligible for transfemoral access, TAVR was associated with significantly better health status compared with SAVR at 1 month. However, at both 1 and 2 years, there were no differences in health status between transfemoral-eligible patients treated with The improvements in health status at 1-and 2-year followup were substantial with both TAVR and SAVR, regardless of access site. With more than 60% of surviving patients experiencing improvements of more than 10 points in the KCCQ-OS score at 2 years, these changes are not only statistically significant but also clinically meaningful, as prior studies in patients with heart failure have shown that improvements as small as 5 points on the KCCQ-OS are associated with reduced mortality and health care costs.
12,21 The magnitude of improvement of QOL in the PARTNER 2A trial was smaller than that seen in both the PARTNER A and CoreValve US Pivotal trials (mean 1-year changes in KCCQ-OS of 19, 27, and 23 points, respectively). 9,10 These findings are likely related to the worse baseline health status seen in patients at high surgical risk (baseline KCCQ-OS score, 39-45 points) compared with the intermediate-risk population in PARTNER 2A (baseline KCCQ-OS score, 53 points). In interpreting our findings, it is important to recognize that the observed health status results apply only to surviving patients at each time interval. If a new treatment results in a survival benefit compared with the alternative, it may paradoxically appear to result in worse long-term health status than the alternative strategy owing to differential attrition of the sickest patients in the alternative treatment arm. As such, integrating both survival and QOL into a single outcome provides an important patient-centered metric by which to further evaluate the effects of TAVR vs SAVR. Indeed, when mortality and health status outcomes were analyzed as a single, ordinal end point, there was evidence of a statistically significant benefit of transfemoral TAVR over SAVR at both early (1 month) and later (1 and 2 years) time points in the transfemoral cohort. While the differences at the later time points were small and driven mainly by a trend toward lower mortality in the TAVR arm, these findings suggest that there may be a sustained overall benefit of transfemoral TAVR over SAVR in this population. Longer term follow-up is needed to assess whether this finding persists.
Although the magnitude of long-term health status benefit was similar with TAVR and SAVR at 1 and 2 years, early health status benefits favored TAVR, but only among patients who were suitable for transfemoral access. These results add to a growing literature demonstrating that TAVR via transthoracic access may not offer significant therapeutic advantages over SAVR. 9, 10 There are a number of possible reasons for these findings. First, although there were lower rates of acute kidney injury, disabling stroke, and atrial fibrillation in patients treated with TAVR vs SAVR in the transfemoral cohort at 1 month, there were no significant differences in complications between TAVR and SAVR in the transthoracic cohort. 6 As such, a lower incidence of these complications could have contributed to more rapid improvement in health status in the transfemoral TAVR patients. Second, manipulation of the chest's musculoskeletal frame required for transthoracic access (whether by lateral thoracotomy or ministernotomy) may cause more postoperative pain than expected. While it is intuitive that a smaller chest incision via a lateral thoracotomy or ministernotomy would be associated with an easier healing process than a traditional median sternotomy used for SAVR, prior studies do not support this hypothesis. [22] [23] [24] Finally, it is possible that transthoracic TAVR results in an early health status benefit compared with SAVR that was not captured by our study, either through power issues or through using scales that were insensitive to modest differences in pain between transthoracic TAVR and SAVR during the early recovery period.
Limitations
Our study should be interpreted in light of several potential limitations. First, as noted above, the proportion of patients in the transthoracic cohort was low (24.0%). As such, the comparisons of transthoracic TAVR with SAVR may have been underpowered to detect modest differences in health status at both early and late time points. Second, the PARTNER 2A trial used the Sapien XT valve, which is a second-generation TAVR device. Since the conduct of this trial, a third-generation, balloon-expandable valve (Sapien 3) has been approved and offers several advantages over the Sapien XT valve, including a lower delivery profile and lower rates of paravalvular regurgitation. 25 Whether use of the Sapien 3 valve would have led to greater health status benefits compared with SAVR is unknown. Third, PARTNER 2A was an unblinded trial, which could have influenced patient-reported health status during follow-up. Finally, there was a modest amount of missing health status data at 2 years (15.7% for SAVR; 11.9% for TAVR). While missing data could have contributed to responder bias, there was no difference in baseline characteristics between patients with and without available health status data at 2 years, thereby suggesting that the effect of responder bias is likely minimal.
Conclusions
Among patients with severe AS at intermediate surgical risk, TAVR and SAVR were associated with similar health status benefits through 2 years of follow-up. Although health status improvement was more rapid with TAVR compared with SAVR, this benefit was seen only in patients treated via transfemoral access. Further studies are needed to assess the durability of health status improvement of TAVR beyond 2 years and to understand the effects of third-generation TAVR devices on health status in patients with severe AS. 
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